Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1-Reference-Cited by-同舟云学术

Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

Published:2023-09 Issue:9 Volume:12 Page:2321-2335
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Aberg Judith A.,Shepherd Bronagh,Wang Marcia,Madruga Jose V.,Mendo Urbina Fernando,Katlama Christine,Schrader Shannon,Eron Joseph J.,Kumar Princy N.,Sprinz Eduardo,Gartland Margaret,Chabria Shiven,Clark Andrew,Pierce Amy,Lataillade Max,Tenorio Allan R.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-023-00870-6.pdf

Reference34 articles.

1. Priest J, Hulbert E, Gilliam BL, Burton T. Characterization of heavily treatment-experienced people with HIV and impact on health care resource utilization in US commercial and Medicare Advantage health plans. Open Forum Infect Dis. 2021;8:ofab562.

2. Puertas MC, Ploumidis G, Ploumidis M, et al. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe. 2020;1:e130–5.

3. Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810–8.

4. Armenia D, Di Carlo D, Flandre P, et al. HIV MDR is still a relevant issue despite its dramatic drop over the years. J Antimicrob Chemother. 2020;75:1301–10.

5. Rukobia [prescribing information]. Durham, NC: ViiV Healthcare; 2022.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate;Antiviral Research;2024-09

2. Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study;HIV Medicine;2024-08-25

3. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study;Frontiers in Immunology;2024-05-28

4. Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach;JAC-Antimicrobial Resistance;2024-05-06

5. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir;BMC Infectious Diseases;2024-02-23